Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)
Titel:
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)
Auteur:
Des Guetz, Gaetan Landre, Thierry Westeel, Virginie Milleron, Bernard Vaylet, Fabien Urban, Thierry Barlesi, Fabrice Souquet, Pierre-Jean Debieuvre, Didier Braun, Denis Fraboulet, Gislaine Monnet, Isabelle Uzzan, Bernard Molinier, Olivier Morin, Franck Moro-Sibilot, Denis Morère, Jean Francois